1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
63D22609EDEC3102400258AAE0032576F
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-oncology-field-medical-excellence-north-america-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2044.210.149.205
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Oncology Field Medical Excellence in North America: Establishing Standards for High Performance & Impact

ID: 5791


Features:

10 Info Graphics

14 Data Graphics

110+ Metrics

7 Narratives


Pages/Slides: 29


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Oncology Field Medical Excellence in North America: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The North American oncology market stands as a dynamic landscape characterized by cutting-edge research, advanced treatments, and evolving patient needs. Amidst a myriad of stakeholders, including influential key opinion leaders and healthcare providers, optimizing the operational efficiency and strategic impact of field medical teams is paramount for oncology manufacturers.

Best Practices, LLC undertook this benchmarking research to empower Oncology Field Medical Excellence leaders in crafting a framework that fosters consistency and maximizes impact in North America. The study provides strategic insights tailored to enhance KOL interactions, evaluate MSL performance, and strategically align staffing footprints.

KEY TOPICS

  • Effective Oncology Field Performance Metrics in North America
  • Building an Oncology Field Medical Excellence Framework
  • Target and Engagement Levels of Oncology KOLs in North America
  • Average Time Oncology MSLs Spend on KOL Interactions and Internal Activities in North America
  • Oncology Field Medical Staffing Footprint in North America
  • Key Insights and Lessons Learned for Measuring the Impact of Oncology MSLs in North America

KEY METRICS

  • North America field scorecard: Benchmarking oncology engagements
  • Average total panel size supported by an individual Oncology MSL in North America
  • Average number of monthly KOL/HCP and F2F meetings in North America – Oncology segment
  • Value assigned to each interaction type on the Oncology MSL scorecard (North America)
  • Engagement metrics for non-tiered Oncology KOLs in North America
  • Average annual field presence of Oncology MSLs in North America
  • Time spent by Oncology MSLs on external, internal, and logistics activities in North America
  • Weekly Oncology MSL time allocation across activity streams in North America
  • Oncology MSL engagement mix in North America
  • Oncology field medical staffing footprint in North America

SAMPLE KEY FINDINGS

  • Emphasis on F2F Interactions in North America: Within the North American oncology field medical teams, a notable trend emerges as half of the teams assign higher value to Face-to-Face (F2F) interactions, recognizing their significant impact on the overall MSL scorecard.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from oncology companies around the world through a custom benchmark survey. Focused on oncology field medical operations, the research drew insights from a diverse range of respondents and was meticulously segmented at regional levels.


Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.